A CEO who sold his last cancer drug company for $12 billion just got $300 million to do it again
Business Insider -


Two executives who helped get one of the first cancer drugs that's part of "a big new field of medicine" approved are back just a few months later with a new startup called Allogene.

This time, they've got $300 million to see if they can pull it off in a less personalized way using new cell therapies licensed in from Pfizer.

Its farthest along treatment is headed into phase 2 clinical trials in 2019. 

Allogene is led by former Kite Pharma executives who sold the company in August 2017...


Related Articles